NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Medicaid -- economics Remove constraint Subjects: Medicaid -- economics Genre Technical Report Remove constraint Genre: Technical Report Copyright Public domain Remove constraint Copyright: Public domain

Search Results

4. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

5. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

8. Schedule H: new community benefit reporting requirements for hospitals

10. Federal subsidies for health insurance coverage for people under age 65: 2018 to 2028

11. Federal mandatory spending for means-tested programs, 2008 to 2028

12. How CBO adjusts for survey underreporting of transfer income in its distributional analyses

14. How CBO and JCT analyze major proposals that would affect health insurance coverage

15. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

16. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

17. How do changes in Medical malpractice liability laws affect health care spending and the federal budget?

19. Medicaid: CMS needs better data to monitor the provision of and spending on personal care services : report to Congressional requesters

20. Medicaid managed care: improved oversight needed of payment rates for long-term services and supports : report to Congressional requesters

22. Medicaid program integrity: CMS should build on current oversight efforts by further enhancing collaboration with states : report to the Chairman, Committee on Finance, U.S. Senate

23. Medicaid demonstrations: federal action needed to improve oversight of spending : report to the Chairman, Committee on Finance, U.S. Senate

24. Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

25. Preliminary analysis of legislation that would replace subsidies for health care with block grants

27. Rebalancing long-term care: the role of the Medicaid HCBS waiver program

28. Medicare and mental health: the fundamentals

29. Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal

31. Shaping Medicaid and SCHIP through waivers: the fundamentals

33. National spending for long-term services and supports (LTSS): the basics

34. Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

35. Telehealth: use in Medicare and Medicaid : testimony before the Subcommittee on Agriculture, Energy, and Trade and Subcommittee on Health and Technology, Committee on Small Business, House of Representatives

36. Medicaid: states fund services for adults in institutions for mental disease using a variety of strategies : report to the Co-Chair, Caucus on International Narcotics Control, U.S. Senate

37. Newborn health: federal action needed to address neonatal abstinence syndrome : report to Congressional addressees

38. Medicaid: Characteristics of and expenditures for adults with intellectual or developmental disabilities : report to congressional requesters

40. The cost of not expanding Medicaid

43. Medicaid eligibility: accurate beneficiary enrollment requires improvements in oversight, data, and collaboration : testimony before the Subcommittee on Health Care, Committee on Finance, U.S. Senate

44. Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees

45. Medicaid: CMS needs more information on states' financing and payment arrangements to improve oversight : report to the Chairman, Committee on Homeland Security and Governmental Affairs, U.S. Senate

46. CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid

48. Medicaid: HHS’s preliminary analyses offer incomplete picture of behavioral health demonstration’s effectiveness : report to Congressional requesters

49. Medicare and Medicaid: COVID-19 program flexibilities and considerations for their continuation : testimony before the Committee on Finance, U.S. Senate

50. Medicaid behavioral health: CMS guidance needed to better align demonstration payment rates with costs and prevent duplication : report to Congressional committees

52. Puerto Rico: efforts to improve competition for Medicaid procurement : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

53. A comparison of brand-name drug prices among selected federal programs

56. Data on Medicaid Managed Care payments to providers are incomplete and inaccurate

57. Opportunities exist to strengthen evaluation and oversight of telehealth for behavioral health in Medicaid

58. Nationwide, almost all Medicaid Managed Care plans achieved their medical loss ratio targets

59. Most Medicare beneficiaries received telehealth services only from providers with whom they had an established relationship

60. States reported multiple challenges with using telehealth to provide behavioral health services to Medicaid enrollees

62. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

66. One percent of drugs with Medicaid reimbursement were not FDA-approved

67. Part D plans generally include drugs commonly used by dual eligibles: 2019

69. Budgetary effects of policies to modify or eliminate Medicaid’s institutions for mental diseases exclusion

70. Exploring the effects of Medicaid during childhood on the economy and the budget

71. Four states reviewed received increased Medicaid COVID-19 funding even though they terminated some enrollees’ coverage for unallowable or potentially unallowable reasons

72. States face ongoing challenges in meeting third-party liability requirements for ensuring that Medicaid functions as the payer of last resort